GW Pharmaceuticals plc
If you purchased GW Pharmaceuticals plc securities and would like to join the action, please click "Join This Action" below.
GWPH MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF GW PHARMACEUTICALS PLC IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – GWPH
February 3, 2021.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether GW Pharmaceuticals plc (NASDAQ: GWPH) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of GW Pharmaceuticals to Jazz Pharmaceuticals plc for $200.00 in cash and $20.00 in Jazz ordinary shares.
On behalf of GW Pharmaceuticals shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.